OBN Digital Event: Hosted by Domainex

Are we seeing long-term shifts in the Scientific Research Landscape?

Friday, 2 Oct '20

This edition of OBN’s Digital Event series is hosted by Domainex and will address how major global events such as the ongoing pandemic is impacting the research focus of R&D companies  - and whether these shifts are temporary or more long term.  Will we see a change in direction in how drugs are developed and the support required by companies throughout each stage of development? 

Keynote Speakers:

  • Tom Mander, CEO of Domainex will share an update on how the function and role of organisations such as Domainex have evolved and where they are heading in the future. What are the areas they are seeing a shift in and what are the factors determining these changes e.g. a focus on infectious diseases or government funding patterns.
  • Ray Boffey, Head of Chemistry at Domainex will share his insight in the evolution of their chemistry pipeline and how taking an integrated approach to medicinal chemistry, biochemistry and computational chemistry can speed up project timelines for R&D companies; showing that effective integration includes brings together scientific teams and embracing innovation.
  • Helen Philippou, Founder Director of LUNAC Therapeutics, 'Drug Discovery: From Academia to Start-Up'. An interesting and unique case study from an R&D company that Domainex have recently collaborated with.